Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors - Trial NCT01713972
Access comprehensive clinical trial information for NCT01713972 through Pure Global AI's free database. This Phase 1 trial is sponsored by Manisha Shah and is currently Completed. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 23 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Manisha Shah
Ohio State University Comprehensive Cancer Center
Timeline & Enrollment
Phase 1
Nov 19, 2012
Dec 26, 2018
Primary Outcome
Incidence of adverse events using Common Terminology Criteria for Adverse Events (CTCAE) v4,Maximum tolerated dose, defined as the dose below the dose where at least 2 dose limiting toxicities (DLTs) are observed, graded using CTCAE v4
Summary
This phase I trial studies the side effects and best dose of dabrafenib and pazopanib
 hydrochloride when given together in treating patients with advanced malignant tumors.
 Dabrafenib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of
 the enzymes needed for cell growth
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT01713972
Non-Device Trial